VE-822 ATR Inhibitor: Precision Sensitization in PDAC Models

Executive Summary: VE-822 is a selective ATR inhibitor with an IC50 of 0.019 μM, enhancing the efficacy of chemoradiotherapy in preclinical pancreatic ductal adenocarcinoma (PDAC) models (source: product_spec). It disrupts ATR-mediated DNA damage response, increasing DNA damage persistence in tumor cells while sparing normal tissues (source: paper). VE-822 is optimally soluble in DMSO at ≥50 mg/mL but insoluble in water and ethanol. Oral administration of VE-822 (60 mg/kg) in mouse xenograft models significantly prolongs tumor growth delay in combination with radiation and gemcitabine, without increasing normal tissue toxicity (source: product_spec). APExBIO supplies VE-822 (SKU: B1383) to the research community, supporting studies in DNA damage signaling, cell cycle regulation, and radiosensitization strategies.

Biological Rationale

ATR (ATM-Rad3-related) kinase is a master regulator of the cellular DNA damage response, particularly in response to replication stress and double-strand DNA breaks (DSBs). Inhibition of ATR sensitizes tumor cells—especially those with p53 and K-Ras mutations, as seen in PDAC—to DNA damaging agents like radiation and gemcitabine (source: strategic_article). Tumor selectivity arises because cancer cells with defective repair pathways rely heavily on ATR for survival under genotoxic stress, whereas normal cells are less dependent. This creates a therapeutic window for selective radiosensitization (source: paper).

Mechanism of Action of VE-822

VE-822 acts as a potent and selective small-molecule inhibitor of ATR kinase, exhibiting a 50% inhibitory concentration (IC50) of 0.019 μM in biochemical assays (source: product_spec). By inhibiting ATR, VE-822 abrogates cell cycle checkpoints, reduces homologous recombination repair, and increases persistent DNA damage in tumor cells exposed to genotoxic treatments. This mechanism underpins its radiosensitizer profile and its synergy with chemotherapeutic agents such as gemcitabine (source: site_article—this article details actionable radiosensitization workflows, while the current article extends with protocol parameters and new clinical context).

Evidence & Benchmarks

• VE-822 inhibits ATR kinase with an IC50 of 0.019 μM (source: product_spec).
• In pancreatic cancer xenograft models, oral administration of VE-822 at 60 mg/kg combined with radiation and gemcitabine significantly prolongs tumor growth delay, with minimal added toxicity to normal tissue (source: product_spec).
• VE-822 selectively radiosensitizes PDAC cells harboring p53 and K-Ras mutations, while sparing normal cells (source: strategic_article; this extends the mechanistic framework to include synthetic lethality and cGAS-mediated stability not deeply covered here).
• VE-822 is soluble at ≥50 mg/mL in DMSO, but insoluble in water or ethanol (source: product_spec).
• Use of induced pluripotent stem cell (iPSC)-based clinical trial selection platforms enables patient-specific drug efficacy prescreening for drugs like VE-822 (source: paper).
• Comparative studies of ATR inhibitors in 2D vs. 3D cancer models emphasize the importance of physiologically relevant systems for radiosensitizer evaluation (source: site_article; the present article focuses on protocol specifics and clinical translation).

Applications, Limits & Misconceptions

VE-822 is widely applied in research involving DNA damage response inhibition, cell cycle checkpoint analysis, and development of radiosensitization strategies in oncology, especially PDAC. It is not intended for direct clinical use, nor is it a pan-cancer radiosensitizer; its efficacy and selectivity are context- and genotype-dependent.

Common Pitfalls or Misconceptions

• VE-822 is not soluble in water or ethanol; DMSO is required for stock solutions (source: product_spec).
• It should not be used as a general DNA damage response inhibitor in non-cancerous cells, as its selectivity is predicated on specific oncogenic mutations (workflow_recommendation).
• Exceeding recommended storage times or conditions may lead to compound degradation; stocks should be kept at -20°C and used short-term (source: product_spec).
• Results from 2D cell models may not translate to 3D or in vivo systems; physiologically relevant assays are recommended for radiosensitization studies (source: site_article).
• VE-822 is not a substitute for ATM or DNA-PKcs inhibitors; its mechanism is specific to ATR (workflow_recommendation).

Workflow Integration & Parameters

Protocol Parameters

• ATR kinase activity assay | IC50 = 0.019 μM | Biochemical ATR inhibition studies | Benchmark for inhibitor potency | product_spec
• Xenograft treatment | 60 mg/kg oral, once daily | Mouse PDAC xenograft radiosensitization | Optimal efficacy with minimal toxicity | product_spec
• Stock solution preparation | ≥50 mg/mL in DMSO | Stock solution for in vitro/in vivo use | Ensures solubility and stability | product_spec
• Storage | -20°C, short-term | All research applications | Maintains compound stability | product_spec
• iPSC-based prescreening | Variable (see reference) | Drug efficacy assessment in patient-derived cells | Personalized medicine applicability | paper

For hands-on workflow recommendations and troubleshooting, see VE-822 ATR Inhibitor: Enhancing DNA Damage Response Studies. That article gives practical advice for optimizing protocols, while this dossier synthesizes clinical rationale and benchmark data.

Conclusion & Outlook

VE-822 (APExBIO, B1383) is a rigorously benchmarked ATR inhibitor supporting advanced research in DNA damage response inhibition, radiosensitization, and precision oncology. Its selective action in PDAC models and compatibility with patient-derived screening platforms highlight its translational value. As iPSC-based prescreening gains traction in drug development, integration of VE-822 into personalized research workflows may accelerate the adoption of genotype-tailored chemoradiotherapy strategies (source: paper). All evidence to date is preclinical; further clinical validation is required.

For more details or to order, visit the VE-822 product page.